Notable anti-PD-1 antibodies like pembrolizumab, nivolumab, cemiplimab, tislelizumab, toripalimab, and camrelizumab, along with anti-PD-L1 antibodies such as atezolizumab, avelumab, and durvalumab, have become integral components of clinical cancer treatment. This evidence concerns the gene CD274 and cancer.